The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Isatuximab on-body injector may improve myeloma care delivery and patient experience
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the potential practice-changing impact of the on-body injector (OBI) formulation of isatuximab in multiple myeloma. He reviews findings from the IRAKLIA (NCT05405166) and IZALCO (NCT05704049) studies, which demonstrated comparable efficacy to intravenous administration with improved convenience, patient experience, and healthcare resource utilization. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
